ARTL Pops 33% on Glaucoma Study Deal, But Don't Ignore the Warning Signs

March 18, 2026 — 2:23 PM EDT

ARTL exploded 33% on glaucoma study news with 72x float volume, but the cash burn and dilution risks make this more squeeze than substance.

$6.435 +32.68% Vol: 51.15M Float: ~708K

Read Report →

Get reports like this in your inbox. Free.

Independent research on momentum stocks, delivered every trading day before the bell.

No spam. No upsells. Unsubscribe anytime.

Recent Research

Recent Reports

ARTL

ARTL Pops 33% on Glaucoma Study Deal, But Don't Ignore the Warning Signs

Mar 18, 2026

ARTL exploded 33% on glaucoma study news with 72x float volume, but the cash burn and dilution risks make this more squeeze than substance.

Read →

VNRX

VNRX Pops 39% on "World-First" Liquid Biopsy Breakthrough Amid Delisting Risks

Mar 18, 2026

VNRX explodes 39% on breakthrough liquid biopsy claims, but massive volume and delisting pressures create a complex risk-reward setup.

Read →

LBGJ

LBGJ: The Anatomy of a 138% Pre-Market Pump — And Why It's Already Unwinding

Mar 18, 2026

LBGJ rockets 138% in pre-market but immediately begins fading from highs, exposing the mechanical nature of the move and underlying dilution risks.

Read →

AIM

AIM ImmunoTech (AIM) Explodes 110% Pre-Market After Japan Patent Win Triggers Fresh Catalyst

Mar 18, 2026

AIM explodes 110% pre-market after securing final Japanese patent approval for Ampligen cancer combination therapy, but dilution risks loom from recent rights offering.

Read →

BIAF

BIAF's Wild March Ride: The Rise, the Hype, and the Reality Check

Mar 17, 2026

bioAffinity Technologies exploded 122% on March 13 earnings, then gave back gains as investors parsed the dilution-heavy reality behind the revenue surge.

Read →

UCAR

UCAR Explodes 67% Pre-Market: Thailand Truck Deal Sparks Skepticism and Opportunity

Mar 17, 2026

UCAR explodes 67% pre-market on Thailand battery-truck news, but the skeptic's math reveals dilution risks that bulls are ignoring in this micro-cap momentum play.

Read →

View All Reports →

About Us

What is Free Equity Reports?

Free Equity Reports is an independent equity research publication that publishes daily analysis on momentum stocks, small-cap companies, and trending market movers.

Each report covers catalysts, SEC filing analysis, dilution risk, float and share structure, and an honest assessment of whether the setup still makes sense for traders.

Reports are written for active retail traders who want real research — not hype, not spam, not recycled press releases. Every report is published free, every trading day, before the market opens.

Don't Miss Tomorrow's Report.

Join traders who read independent research before the market opens.

No spam. No upsells. Unsubscribe anytime.